Table 1.

Clinical stage antibody therapeutic Fv domains with extremes of charge.

Identifier	Isotype	Clinical status*	ABSASA Hydrophobicity (Å2)	Fv domain net charge
				pH 7.4	pH 5.0
Lenzilumab	IgG1	discontinued	492.6	9	10
Foralumab	IgG1	discontinued	539.2	7	9
Alemtuzumab	IgG1	approved	451.3	6	8
Basiliximab	IgG1	approved	508.4	6	9
Bimagrumab	IgG1	discontinued	534.1	6	7
Briakinumab	IgG1	discontinued	474.4	6	10
Dacetuzumab	IgG1	discontinued	554.0	6	10
Gantenerumab	IgG1	phase 3	525.6	6	7
Imgatuzumab	IgG1	discontinued	474.1	6	8
Rituximab	IgG1	approved	532.6	6	8
Sifalimumab	IgG1	discontinued	459.6	6	6
Tocilizumab	IgG1	approved	474.3	6	8
Blosozumab	IgG4P	discontinued	517.9	−3	−1
Infliximab	IgG1	approved	591.3	−3	1
Omalizumab	IgG1	approved	470.6	−3	1
Mavrilimumab	IgG4	discontinued	668.7	−4	−2
Duligotuzumab	IgG1	discontinued	622.4	−5	−4

*Clinical status is dynamic, discontinued status can alter; assignments correct as of October 2022.^35,36